These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16449540)

  • 1. Modified-release tacrolimus.
    Chisholm MA; Middleton MD
    Ann Pharmacother; 2006 Feb; 40(2):270-5. PubMed ID: 16449540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplant Proc; 2005 Mar; 37(2):867-70. PubMed ID: 15848559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients.
    Comuzzi C; Lorenzin D; Rossetto A; Faraci MG; Nicolini D; Garelli P; Bresadola V; Toniutto P; Soardo G; Baroni GS; Adani GL; Risaliti A; Baccarani U
    Transplant Proc; 2010 May; 42(4):1320-1. PubMed ID: 20534291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels.
    Crespo M; Mir M; Marin M; Hurtado S; Estadella C; Gurí X; Rap O; Moral R; Puig JM; Lloveras J
    Transplant Proc; 2009; 41(6):2115-7. PubMed ID: 19715848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients.
    Florman S; Alloway R; Kalayoglu M; Punch J; Bak T; Melancon J; Klintmalm G; Busque S; Charlton M; Lake J; Dhadda S; Wisemandle K; Wirth M; Fitzsimmons W; Holman J; First MR
    Transplantation; 2007 Jun; 83(12):1639-42. PubMed ID: 17589349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation.
    Wente MN; Sauer P; Mehrabi A; Weitz J; Büchler MW; Schmidt J; Schemmer P
    Clin Transplant; 2006; 20 Suppl 17():80-4. PubMed ID: 17100706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified release tacrolimus.
    First MR; Fitzsimmons WE
    Yonsei Med J; 2004 Dec; 45(6):1127-31. PubMed ID: 15627307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First clinical experience with the new once-daily formulation of tacrolimus.
    First MR
    Ther Drug Monit; 2008 Apr; 30(2):159-66. PubMed ID: 18367975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplantation; 2007 Jun; 83(12):1648-51. PubMed ID: 17589351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen.
    Florman S; Alloway R; Kalayoglu M; Lake K; Bak T; Klein A; Klintmalm G; Busque S; Brandenhagen D; Lake J; Wisemandle K; Fitzsimmons W; First MR
    Transplant Proc; 2005 Mar; 37(2):1211-3. PubMed ID: 15848672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients.
    Alloway RR; Eckhoff DE; Washburn WK; Teperman LW
    Liver Transpl; 2014 May; 20(5):564-75. PubMed ID: 24493215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once- versus twice-daily tacrolimus: are the formulations truly equivalent?
    Barraclough KA; Isbel NM; Johnson DW; Campbell SB; Staatz CE
    Drugs; 2011 Aug; 71(12):1561-77. PubMed ID: 21861541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations.
    Grinyó JM; Petruzzelli S
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1567-79. PubMed ID: 25407098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients.
    Garnock-Jones KP
    Drugs; 2015 Feb; 75(3):309-20. PubMed ID: 25613762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2014 Jul; 17(7):520-6. PubMed ID: 24754700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan.
    Uemoto S; Abe R; Horike H; So M
    Transplant Proc; 2014 Apr; 46(3):749-53. PubMed ID: 24767340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients.
    Lu Z; Bonate P; Keirns J
    Br J Clin Pharmacol; 2019 Aug; 85(8):1692-1703. PubMed ID: 30950096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.